References
- Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247–1253.
- Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood 1996;88:1390–1398.
- Duffield AS, Aoki J, Levis M, et al. Clinical and pathologic features of secondary acute promyelocytic leukemia. Am J Clin Pathol 2012;137:395–402.
- Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972–1976.
- Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123–2137.
- Elliott MA, Letendre L, Tefferi A, et al. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. Eur J Haematol 2012;88:237–243.
- Larson RA, Le Beau MM. Prognosis and therapy when acute promyelocytic leukemia and other “good risk” acute myeloid leukemias occur as a therapy-related myeloid neoplasm. Mediterr J Hematol Infect Dis 2011;3:e2011032.
- Swerdlow SH, Campo E, Harris NL, et al editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 127–129.
- Tansley S, Gibbons S. Capecitabine-induced acute myeloid leukaemia. N Z Med J 2009;122:118–119.
- Shapiro S, Hughes G, Al-Obaidi MJ, et al. Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer. Eur J Haematol 2007;78:543–544.
- Bhavnani M, Wolstenholme RJ. Razoxane and acute promyelocytic leukaemia. Lancet 1987;2:1085.
- Merrouche Y, Mugneret F, Cahn JY. Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer. Ann Oncol 2006;17:1025–1026.